This site is intended for healthcare professionals

Additional data from 4 year update of ongoing phase 1/II study of valoctocogene roxaparvovec gene therapy for severe hemophilia A presented at World Federation of Hemophilia virtual summit.- BioMarin

Read time: 3 mins
Last updated:16th Mar 2021
Published:18th Jun 2020
Condition: Haemophilia A
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest